Glioblastoma: new therapeutic strategies to address cellular and genomic complexity

Oncotarget. 2017 Dec 20;9(10):9540-9554. doi: 10.18632/oncotarget.23476. eCollection 2018 Feb 6.

Abstract

Glioblastoma (GBM) is the most invasive and devastating primary brain tumor with a median overall survival rate about 18 months with aggressive multimodality therapy. Its unique characteristics of heterogeneity, invasion, clonal populations maintaining stem cell-like cells and recurrence, have limited responses to a variety of therapeutic approaches, and have made GBM the most difficult brain cancer to treat. A great effort and progress has been made to reveal promising molecular mechanisms to target therapeutically. Especially with the emerging of new technologies, the mechanisms underlying the pathology of GBM are becoming more clear. The purpose of this review is to summarize the current knowledge of molecular mechanisms of GBM and highlight the novel strategies and concepts for the treatment of GBM.

Keywords: CRISPR/Cas9 genome editing; gene therapy; glioblastoma; immunotherapy; molecular mechanisms.

Publication types

  • Review